세계의 파머징(Pharmerging) 시장 규모, 점유율, 성장 분석 : 제품별, 경제 규모별, 적응증별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Pharmerging Market Size, Share, Growth Analysis, By Product (Pharmaceutical, Other Healthcare Verticals), By Economy (Tier-1, Tier-2), By Indication, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1630744
리서치사:SkyQuest
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
파머징 세계 시장 규모는 2023년 1조 8,000억 달러로 평가되었습니다. 2024년 1조 8,900억 달러에서 2032년 2조 8,400억 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 5.2%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
세계 파머징 시장은 비감염성 질환의 확산, 평균 수명 증가, 1인당 소득 증가, 정부 의료비 지출 증가 등 몇 가지 중요한 요인으로 인해 크게 성장할 것으로 예상됩니다. 인구의 고령화는 환자의 예후를 개선하기 위한 첨단 및 혁신적 의료 제품에 대한 수요를 더욱 증가시키고 있습니다. 신제품 출시가 활발하여 향후 5년간 약 300개의 신약이 출시될 것으로 예상되며, 특히 전문의약품, 틈새 시장, 희귀의약품 부문에서 두드러진 성장이 예상되며, 1,960억 달러의 지출이 예상됩니다. 그러나 이 시장은 기존 업체들 간의 치열한 경쟁과 미개발된 사업 기회를 노리는 신규 업체들의 꾸준한 유입으로 특징지어지며 역동적이고 진화하는 시장 상황을 형성하고 있습니다.
Global Pharmerging Market size was valued at USD 1.8 trillion in 2023 and is poised to grow from USD 1.89 trillion in 2024 to USD 2.84 trillion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).
The global pharmerging market is poised for significant growth driven by several pivotal factors including the increasing prevalence of non-communicable diseases, rising life expectancy, heightened per capita income, and escalated government healthcare spending. The aging population further intensifies the demand for advanced and innovative medical products aimed at improved patient outcomes. Proliferation in new product launches, with approximately 300 new drugs expected in the next five years-especially in specialty, niche, and orphan categories-signals a noteworthy expansion, projected to generate USD 196 billion in spending. However, the market is marked by fierce competition among established players and a steady influx of new entrants targeting untapped opportunities, shaping a dynamic and evolving landscape ahead.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmerging market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pharmerging Market Segmental Analysis
Global Pharmerging Market is segmented by Product, Economy, Indication, Distribution Channel and region. Based on Product, the market is segmented into Pharmaceutical and Other Healthcare Verticals. Based on Economy, the market is segmented into Tier-1, Tier-2 and Tier-3. Based on Indication, the market is segmented into Lifestyle Diseases, Cancer & Autoimmune Diseases, Infectious Diseases and Others. Based on Distribution Channel, the market is segmented into Hospitals, online stores, retail pharmacies and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pharmerging Market
The global pharmerging market is propelled by several key factors, including the high incidence of chronic diseases, increased awareness among consumers regarding early disease detection and treatment options, and ongoing advancements in research and development. Additionally, rising life expectancy plays a significant role in this market's growth. Government initiatives in emerging economies like India, China, and Indonesia further enhance consumer awareness about pharmaceutical innovations. The proliferation of insurance companies offering diverse coverage to reduce the financial burden of pharmerging treatments also boosts demand for pharmaceuticals worldwide. A pertinent example is Hexvix, which has been added to the 2022 Lecheng Global Specialty Drug Insurance Drug List for bladder cancer diagnosis.
Restraints in the Global Pharmerging Market
The growth of the global Pharmerging market may face significant challenges due to concerns related to intellectual property protection and socio-political factors affecting cross-border transactions. Additionally, stringent price controls could lead to value erosion, further restraining market expansion in the upcoming years. Moreover, the stringent approval processes imposed by government regulatory bodies for the introduction and use of pharmaceuticals can hinder market growth throughout the forecast period. These factors collectively pose substantial risks that could limit the potential development and profitability of the Pharmerging market in a fluctuating global landscape.
Market Trends of the Global Pharmerging Market
The global pharmerging market is witnessing robust growth driven by heightened R&D activities in biotechnology, immunology, and oncology sectors, which are reshaping healthcare paradigms. Major pharmaceutical companies are prioritizing the development of innovative technologies that enhance user convenience and improve patient outcomes. Additionally, the rapid increase in global population, coupled with rising disease prevalence, is further propelling demand for advanced healthcare solutions. This synergy of innovation and necessity is fostering an environment ripe for investment and expansion in emerging markets, making them pivotal players in the global pharmaceutical landscape as they seek to address both local and global health challenges.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Pharmerging Market Size by Product & CAGR (2025-2032)
Market Overview
Pharmaceutical
Patented Prescription Drugs
Generic Prescription Drugs
OTC Drugs
Other Healthcare Verticals
Medical Device
Clinical Diagnostics
Others
Global Pharmerging Market Size by Economy & CAGR (2025-2032)
Market Overview
Tier-1
Tier-2
Tier-3
Global Pharmerging Market Size by Indication & CAGR (2025-2032)
Market Overview
Lifestyle Diseases
Cancer & Autoimmune Diseases
Infectious Diseases
Others
Global Pharmerging Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospitals
online stores
retail pharmacies
others
Global Pharmerging Market Size & CAGR (2025-2032)
North America (Product, Economy, Indication, Distribution Channel)
US
Canada
Europe (Product, Economy, Indication, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Product, Economy, Indication, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Product, Economy, Indication, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Product, Economy, Indication, Distribution Channel)
